Please assess the completion status of the following clinical trial:

Trial Title: Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Microscopic diagnosis of NSCLC stages IIIB (with malignant pleural effusion) and IV~2. Having adequate tissue sample to perform the markers testing~3. Age ≥ 18 years~4. No prior chemotherapy treatment for lung cancer (Surgery and radiotherapy are acceptable)~5. No other concurrent cancer treatment~6. Performance status of 0- 2 per ECOG scale (Appendix II)~7. Adequate laboratory values as follows as follows:~   Absolute neutrophil count ≥ 1500/mm3 Platelet count ≥100, 000/ mm3 Total bilirubin ≤ 1.25X institutional upper normal level AST and ALT ≤ 3 X institutional upper normal level Serum creatinine ≤ 1.5 X institutional upper normal level~8. Presence of measurable disease~Exclusion Criteria:~1. Prior systemic treatment for lung cancer~2. History of hypersensitivity to drugs used~3. Diagnosis of other malignancy in the last 5 years excluding curatively treated non-melanoma skin cancer and in-situ cervical cancer~4. Medical illness that puts the patient at significant risk per investigator's discretion~5. Uncontrolled CNS disease. Patients with CNS metastatic disease treated with radiotherapy or surgery will be eligible if the CNS disease is stable 4 weeks after the treatment initiation without increase dose of steroids~6. Positive pregnancy test or refusal to use contraception during treatment. (Gynecology consultant for contraception)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin,Docetaxel,Gemzar, Premetrexed (Type: EXPERIMENTAL): Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.

Based on this trial design, predict the completion outcome and termination type (if applicable).